Oral influenza vaccination with live attenuated viruses. 2. Protective efficacy during a type A(H3N2) epidemic

Boll Ist Sieroter Milan. 1975 Oct 20;54(4):323-30.

Abstract

151 subjects, orally immunized with live attenuated influenza virus of the Institute for Viral Preparations of Moscow (bivalent A(H3N2) England 72 and B vaccine) and 66 non vaccinated cohabitants were studied during an epidemic caused by strains similar to A/Port Chalmers/73. 5 cases of disease were virologically or serologically ascertained among the vaccinated (morbidity 3.3%) and 8 among the non-immunized cohabitants (12.1%). The difference turned out statistically significant. By comparing the incidence of the disease in the two groups the protection resulting from vaccination was 72.6%.

MeSH terms

  • Administration, Oral
  • Disease Outbreaks
  • Humans
  • Influenza A Virus, H3N2 Subtype
  • Influenza A virus / immunology
  • Influenza Vaccines / administration & dosage*
  • Influenza, Human / prevention & control*
  • Vaccination / standards*
  • Vaccines, Attenuated

Substances

  • Influenza Vaccines
  • Vaccines, Attenuated